Literature DB >> 19951182

Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Pritish K Tosh1, Richard B Kennedy, Robert A Vierkant, Robert M Jacobson, Gregory A Poland.   

Abstract

Despite a safe and effective vaccine, endemic rubella remains a problem in developing countries. Isolated cases and outbreaks can occur in areas with high vaccine coverage. Individuals, especially pregnant women who remain unimmunized or do not seroconvert, are susceptible to infection and their infants are at risk for congenital rubella syndrome (CRS). Both humoral and cellular immune responses contribute to immune protection. Classically, immunity to rubella has been assessed through the detection of rubella-specific antibody titers. In this study we examined correlates of both humoral and cellular immunity in a large population of immunized young adults in Olmsted County, MN. We were unable to find any significant correlation between cytokine production after in-vitro rubella stimulation and serum antibody titers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19951182      PMCID： PMC2831647          DOI： 10.1089/vim.2009.0068

Source DB:  PubMed          Journal:  Viral Immunol        ISSN： 0882-8245            Impact factor:   2.257


  38 in total

1.  Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein.

Authors:  G T Nepom; M E Domeier; D Ou; S Kovats; L A Mitchell; A J Tingle
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

2.  Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States.

Authors:  S A Plotkin; J D Farquhar; P L Ogra
Journal:  JAMA       Date:  1973-08-06       Impact factor: 56.272

3.  Cell-mediated immunity in rubella assayed by cytotoxicity of supernatants from rubella virus-stimulated human lymphocyte cultures.

Authors:  T Vesikari; G Y Kanra; E Buimovici-Klein; L Z Cooper
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

4.  Elevated serum levels of interleukin-10 in children with acute rubella infection.

Authors:  I Akaboshi; I Nagayoshi; M Omura; K Iwaki
Journal:  Scand J Infect Dis       Date:  2001

5.  Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype.

Authors:  D Ou; L A Mitchell; D Décarie; A J Tingle; G T Nepom
Journal:  Hum Immunol       Date:  1998-03       Impact factor: 2.850

6.  Case isolation and contact tracing can prevent the spread of smallpox.

Authors:  Martin Eichner
Journal:  Am J Epidemiol       Date:  2003-07-15       Impact factor: 4.897

7.  Analysis of gene expression in fetal and adult cells infected with rubella virus.

Authors:  Maria Pilar Adamo; Marta Zapata; Teryl K Frey
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

8.  Response surface methodology to determine optimal cytokine responses in human peripheral blood mononuclear cells after smallpox vaccination.

Authors:  Jenna E Ryan; Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  J Immunol Methods       Date:  2008-11-25       Impact factor: 2.303

9.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

Review 10.  The relevance of cytokines for development of protective immunity and rational design of vaccines.

Authors:  Jose A Chabalgoity; Adriana Baz; Analía Rial; Sofía Grille
Journal:  Cytokine Growth Factor Rev       Date:  2007-03-07       Impact factor: 7.638
View more
  8 in total

1.  Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.

Authors:  Benjamin J Umlauf; Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Correlations between vaccinia-specific immune responses within a cohort of armed forces members.

Authors:  Benjamin J Umlauf; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2011-09-29       Impact factor: 2.257

4.  High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers.

Authors:  Nathaniel D Lambert; V Shane Pankratz; Beth R Larrabee; Adaeze Ogee-Nwankwo; Min-hsin Chen; Joseph P Icenogle; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.

Authors:  Stephen N Crooke; Inna G Ovsyannikova; Richard B Kennedy; Nathaniel D Warner; Gregory A Poland
Journal:  Vaccine       Date:  2020-11-04       Impact factor: 3.641

7.  Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts.

Authors:  Nathaniel D Lambert; Iana H Haralambieva; Inna G Ovsyannikova; Beth R Larrabee; V Shane Pankratz; Gregory A Poland
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

8.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.